MAPT and Alzheimer disease: Previous studies have rarely focused only on the contribution of Tau and Aβ proteins to constructing AD diagnostic models, often incorporating some other biomarkers (Gaetani et al., 2021; Ficiarà et al., 2021; Franciotti et al., 2023; Khan et al., 2024).